Trastuzumab and other drugs called monoclonal antibodies that target HER2 have been quite successful as treatments for HER2-positive breast
All breast cancers are tested for HER2 status to help guide treatment. If a tumor is HER2-positive, the HER2-targeted therapy drug trastuzumab (Herceptin) is
The co-expression of endocrine receptors and HER2, albeit associated with resistance to hormonal and anti-HER2 therapy, resulting in worse prognosis, creates an opportunity of combination treatment, consisting of anti-HER2 drugs and ET, in particular when dual HER2-blockade is used.
If the IHC result is 1, the cancer is considered HER2-negative. These cancers do not usually respond to treatment with drugs that target HER2, but new research shows that certain HER2 drugs might help in some cases (see below). If the IHC result is 2, the HER2 status of the tumor is not clear and is called equivocal. This means that the
Trastuzumab is a landmark drug for the anti-HER2 treatment. It changes the treatment pattern and prognosis in HER2-positive breast cancer patients. One-year treatment with trastuzumab is a
Anti-HER2 therapy has revolutionized the treatment of HER2-positive breast cancer. However, HER2 has emerged as a driver of various other cancers and the indications for HER2-targeted therapy have
The first anti-HER2 drug, Herceptin, received approval in 2024 to treat HER2-positive breast cancer. Since then, many more anti-HER2 drugs have joined the list of approved treatments.
Anti-HER2 drugs for the treatment of advanced HER2 positive breast cancer. Last Updated: Thursday, Decem. In this review article
Herceptin is a HER2/neu receptor antagonist indicated for: The treatment of HER2-overexpressing breast cancer. (1.1, 1.2) The treatment of HER2-overexpressing metastatic gastric or
Comments
4*